^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    BCDx Monitoring Test

    Company:
    Early Is Good
    Type:
    Laboratory Developed Test
    Details
    Evidence

    News

    1year
    TNBC-DX Genomic Test Predicts High pCR in Triple-Negative Breast Cancer with sTILs ≥30% Treated with Neoadjuvant Docetaxel-Carboplatin with/without Pembrolizumab. (SABCS 2024)
    The TNBC-DX genomic test effectively predicts pCR to neoadjuvant TCb ± pembrolizumab in TNBC. Notably, the TNBC-DX pCR-high group identifies patients with high sTILs who have a pCR rate exceeding 90% when treated with TCb+P. This study confirms that gene expression and sTILs provide distinct and potentially complementary information for pCR prediction in TNBC.
    Clinical • PD(L)-1 Biomarker
    |
    BCDx Monitoring Test • TNBCDX®
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel
    1year
    Early is Good Receives NIH Phase 2 grant to develop innovative bladder cancer monitoring test (360Dx)
    " Early is Good (EIG)...has received a National Institutes of Health (NIH) Phase 2 grant of $1.6M in non-dilutive funding to support validation efforts of its bladder cancer monitoring test, BCDx. This non-invasive urine test is the first multi-omic test, making it a more accurate, affordable, and patient-friendly way to monitor bladder cancer recurrence."
    Grant
    |
    BCDx Monitoring Test